In the News

Check back regularly for the latest news and announcements regarding Coyne Scientific, its latest scientific breakthroughs, its services, and its people.

JUNE 4, 2018: SLAS DISCOVERY PUBLISHES GROUND-BREAKING NEW ARTICLE – “CLINICAL TRIALS IN A DISH: A PERSPECTIVE ON THE COMING REVOLUTION IN DRUG DEVELOPMENT”

ATLANTA – June 4, 2018

SLAS Discovery, a leading peer-reviewed scientific journal, today announced the publication of a ground-breaking new article by Coyne Scientific co-authors Bernard Fermini, Ph.D., Kevin P. Coyne, MBA and Shawn T. Coyne, MBA titled, “Clinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development”. The article – which describes a novel drug safety testing paradigm that bridges the worlds of preclinical testing and clinical trials – can be accessed for free ahead-of-print on the publisher’s website at: http://journals.sagepub.com/doi/full/10.1177/2472555218775028.

According to Bernard Fermini, Chief Scientific Officer: “The cost of developing new drugs has reached unsustainable levels, fueled in large part by high attrition rates in clinical development. Recent studies have shown that individual drug susceptibility in a population of volunteers with unknown genetic background can be recapitulated in human induced pluripotent stem cells (hiPSCs) derived from these same individuals, providing a proof of concept for in vitro preclinical trials, and enabling cell-based screening for safety and toxicity at the level of a population, similar to clinical trials. This new platform, termed “Clinical Trials in a Dish”, or CTiD, allows researchers to define the incidence and distribution of effects of drugs (whether beneficial or adverse) across a population long before actual clinical trials, so that a pharma company can curtail development of ‘future failures’ early on while continuing development of safe compounds that might not have met traditional safety margins.”

Added Kevin Coyne, CEO: “CTiD studies, which first became commercially available earlier this year, can also help pharma companies address such important issues as repurposing shelved compounds, reducing adverse drug-drug interactions, protecting underserved ethnic populations, and protecting children and geriatric patients – economically, and without regulatory complications.”

To discover how this new platform offers the potential to revolutionize safety and toxicity testing of new drugs, and/or for more information, please contact Shawn Coyne, President, at scoyne@coynesci.com.

* * *

Posted in Publications | Leave a comment

FEBRUARY 15, 2018: COYNE SCIENTIFIC TO UNVEIL WORLD’S FIRST COMMERCIALLY-AVAILABLE “CLINICAL TRIALS IN A DISH” AT SOCIETY OF TOXICOLOGY’S ANNUAL MEETING

ATLANTA – February 15, 2018 Coyne Scientific, LLC (Atlanta, GA) announced today that it will unveil the world’s first commercially-available “Clinical Trials In A Dish” at the Society of Toxicology’s 2018 Annual Meeting, which runs from March 11-15 in San Antonio, TX. What does the company mean by “Clinical Trials In A Dish”? According to […]

Posted in Conference Presentations | Leave a comment

OCTOBER 24, 2017: COYNE SCIENTIFIC HIGHLIGHTED IN RESEARCH & INNOVATION SESSION AT THE GEORGIA BIO SUMMIT

ATLANTA – October 24, 2017 Coyne Scientific was selected to present on a panel of three speakers discussing “Research & Innovation: Leveraging Stem Cells to Generate Scientific Breakthroughs and Stimulate Economic Development in Georgia: Game-Changing News“. CEO Kevin Coyne and Sr. Director of Data Science & Operations Eli Fine Ph.D. will be at the Georgia […]

Posted in Conference Presentations | Leave a comment

APRIL 17, 2017: COYNE SCIENTIFIC ANNOUNCES APPOINTMENT OF JEROME CHAL, PH.D. AS DIRECTOR OF RESEARCH & DEVELOPMENT

ATLANTA – April 17, 2017 Coyne Scientific, LLC (Atlanta, GA) today announced the appointment Jerome Chal, Ph.D. as Director of Research & Development, effective March 31. Dr. Chal has experience spearheading induced pluripotent stem (iPS) cell-based research projects aimed at characterizing and evaluating iPS cell-derived myogenic cell types as preclinical models. He also has eight […]

Posted in New Team Members | Leave a comment

NOVEMBER 22, 2016: COYNE SCIENTIFIC ANNOUNCES APPOINTMENT OF BERNARD FERMINI, PH.D. AS CHIEF SCIENTIFIC OFFICER AND VICE PRESIDENT OF SAFETY & TOXICOLOGY ASSESSMENT

ATLANTA – November 22, 2016 Coyne Scientific, LLC (Atlanta, GA) today announced the appointment of Bernard Fermini, Ph.D. as Chief Scientific Officer and Vice President of Safety & Toxicology Assessment, effective January 1, 2017. Dr. Fermini will be responsible for providing high-level scientific leadership, ensuring the quality of science for the company’s safety and toxicology […]

Posted in New Team Members | Leave a comment